X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (6) 6
female (6) 6
humans (6) 6
male (6) 6
middle aged (6) 6
aged (4) 4
index medicus (4) 4
administration, oral (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
biological availability (2) 2
cancer (2) 2
carbolines - administration & dosage (2) 2
carbolines - pharmacology (2) 2
chemotherapy (2) 2
cross-over studies (2) 2
cytochrome p-450 enzyme system - genetics (2) 2
cytochrome p-450 enzyme system - metabolism (2) 2
disease-free survival (2) 2
drug interactions (2) 2
half-life (2) 2
hematology, oncology and palliative medicine (2) 2
isoenzymes - genetics (2) 2
isoenzymes - metabolism (2) 2
metabolic clearance rate (2) 2
monoclonal antibodies (2) 2
mortality (2) 2
neoplasm staging (2) 2
oncology (2) 2
predictors (2) 2
pulmonary arterial hypertension (2) 2
pulmonary hypertension (2) 2
registries (2) 2
rheumatology (2) 2
scleroderma (2) 2
scleroderma, systemic - complications (2) 2
serotonin antagonists - pharmacology (2) 2
systemic scleroderma (2) 2
time factors (2) 2
1st-line taxane/carboplatin (1) 1
aflibercept (1) 1
alprazolam - administration & dosage (1) 1
alprazolam - pharmacokinetics (1) 1
angiogenesis (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antidepressive agents, second-generation - metabolism (1) 1
antidepressive agents, second-generation - pharmacokinetics (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antinuclear antibody (1) 1
arterial-hypertension (1) 1
article (1) 1
autoantibodies (1) 1
autoantibodies - blood (1) 1
autoimmunity (1) 1
base-line characteristics (1) 1
bevacizumab (1) 1
biology, biostatistics (1) 1
biostatistics (1) 1
bms099 (1) 1
budesonide (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
canada (1) 1
cancer therapies (1) 1
carbolines - adverse effects (1) 1
carcinoma (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
care and treatment (1) 1
centromere antibody (1) 1
cetuximab (1) 1
chemotherapy plus cetuximab (1) 1
clinical trials (1) 1
clinical-trial (1) 1
colon - drug effects (1) 1
colonic diseases, functional - drug therapy (1) 1
colorectal cancer (1) 1
colorectal neoplasms - drug therapy (1) 1
colorectal neoplasms - pathology (1) 1
crohn disease (1) 1
development and progression (1) 1
disease progression (1) 1
dissertations, academic (1) 1
docetaxel (1) 1
drug administration schedule (1) 1
drug therapy (1) 1
endothelial growth factors (1) 1
endothelial growth-factor (1) 1
epidermal growth factor (1) 1
flex (1) 1
fluorouracil (1) 1
fluorouracil - administration & dosage (1) 1
fluoxetine - administration & dosage (1) 1
fluoxetine - adverse effects (1) 1
fluoxetine - analogs & derivatives (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1326 - 1336
Summary Background Available preclinical and phase 2 clinical data suggest that the addition of cetuximab, a monoclonal antibody directed against the epidermal... 
Hematology, Oncology and Palliative Medicine | PANITUMUMAB | SUPPORTIVE CARE | MULTICENTER | CHEMOTHERAPY PLUS CETUXIMAB | CLINICAL-TRIAL | ONCOLOGY | 1ST-LINE TAXANE/CARBOPLATIN | FLEX | BMS099 | METASTATIC COLORECTAL-CANCER | III TRIAL | Lung Neoplasms - drug therapy | Glutamates - adverse effects | Guanine - analogs & derivatives | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Lung Neoplasms - pathology | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Treatment Failure | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Cetuximab | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Pemetrexed | Disease Progression | Canada | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Neoplasm Staging | Guanine - administration & dosage | Chemotherapy | Epidermal growth factor | Docetaxel | Clinical trials | Monoclonal antibodies | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
01/1998, ISBN 9780612306912
Objectives. To compare the results of meta- and mega-analysis using three randomized controlled trials of oral budesonide for maintenance of remission in... 
Biostatistics | Pharmaceuticals
Dissertation
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.